MapLight Therapeutics, Inc.·3

Oct 27, 5:00 PM ET

Novo Holdings A/S 3

3 · MapLight Therapeutics, Inc. · Filed Oct 27, 2025

Insider Transaction Report

Form 3
Period: 2025-10-25
Novo A/S
10% Owner
Holdings
  • Series C Preferred Stock

    Voting Common Stock (1,558,999 underlying)
  • Series D Preferred Stock

    Voting Common Stock (1,174,682 underlying)
Footnotes (1)
  • [F1]The Series C Preferred Stock and Series D Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

Documents

1 file
  • 3
    form3-10272025_081056.xmlPrimary